Sight Diagnostics Stock

sightdx.com/en-usHealthcareFounded: 2012

Sight Diagnostics is an Israeli medical devices startup that’s using AI technology to speed up blood testing. Its mission is to change the way blood testing is done by providing fast, convenient and accurate diagnostics in a compact platform designed for use in any clinical setting, overseen by CLIA certified lab. Developed over almost a decade of research, its technology combines the latest innovations in blood sample preparation, optics, chemistry, biology, physics and computer science. Its first product, Parasight™, has diagnosed malaria in nearly 1 million tests across 24 countries. Sight OLO®, their latest blood analyzer, digitizes blood with only 2 drops of a finger prick or venous sample and provides lab-grade CBC results in minutes.

Register for Details

For more details on financing and valuation for Sight Diagnostics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Sight Diagnostics.

Register Today

Sight Diagnostics investors also invested in these private companies

BridgeOne Capital China
Longliv Ventures
Microtech Ventures
ForMED Ventures
Emery Capital

Team

Management Team

Daniel Levner
Co-Founder
Amir Ben Shitrit
Chief Operating Officer
Ron Melts
US General Manager
Eran Rubens
Chief Product Officer
Nitsan Maayan-Rabinowich
Chief of Staff

Other companies like Sight Diagnostics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM